

## Alsharedi, M. Resume 2025

---

### Mohamed Alsharedi, MD, FACP

Associate Professor of Medicine- Hematology/ Oncology Department, Markey Cancer Center at Lexington Clinic/ University of Kentucky

EMAIL:

[alsharedi@gmail.com](mailto:alsharedi@gmail.com)

[mal280@uky.edu](mailto:mal280@uky.edu)

---

### Education:

- Tripoli University, Faculty of medicine Tripoli / Libya Medical Doctorate ( MD) April 2004
  - ABIM Board Certified in Internal Medicine, Medical Oncology and Hematology
- 

### Postdoctoral / Residency & Fellowship training

- Medical Oncology Fellowship 2013-2015 ( Marshall University , USA)
  - Internal Medicine Residency 2010-2013 ( Marshall University, USA)
  - Bone Marrow Transplant 2014 ( Ohio State University, USA)
  - Internal Medicine & Hematology 2007-2010 ( Tripoli Central Hospital, Libya)
- 

### Certificates:

- American Board of Hematology : December 2020
  - American Board of Medical Oncology: October 2015
  - American Board of Internal Medicine: August 2013
  - ECFMG June 2008
- 

### Academic appointment:

- Associate Professor of Medicine at University of Kentucky 01/2021- Present
  - Associate Professor of Medicine at Marshall University 6/2020-12/2020
  - Assistant Professor of Medicine at Marshall University 9/2015- 6/2020
- 

### Work Experience:

- Hematology/Medical Oncology : Markey Cancer Center at Lexington Clinic/ University of Kentucky in Lexington and Richmond , Kentucky , USA ( January 2021- Present)
  - Hematology/Medical Oncology : Edwards Comprehensive Cancer Center/Marshall University in Point Pleasant and Huntington, West Virginia, USA ( Sep 2015 – December 2020)
- 

### Medical License :

Kentucky state Medical License ( 2019- Present)  
West Virginia state Medical License ( 2013- Present )

---

### Awards:

- Chief fellow 2014-2015
  - Fellow of American College of Physicians
  - Recognition of research project by American Society of Clinical Oncology Journal (The ASCO Post- May 10, 2015)
  - Research award American college of Physician October 2014 ( ACP WV Chapter)
- 

#### **Professional Societies membership:**

- Fellow of American college of Physician FACP
  - American Society of Clinical Oncology ASCO
  - American Society of Hematology ASH
- 

#### **Committee memberships/Leadership (Hospital and School of Medicine)**

- Personnel Advisory Committee for faculty promotion Marshall University ( 2019-2020)
- Quality Improvement Committee , Edwards Com. Cancer Center ( 2015-2020)
- Hematology and Medical Oncology fellowship recruiting committee ,Marshall University School of Medicine ( 2015-2020)
- Hematology and Medical Oncology fellowship Clinical Competency Committee, Marshall University School of Medicine ( 2015-2020)
- Executive Committee Pleasant Valley Hospital ( West Virginia) 2015-2020
- Cabell Huntington Hospital Ethics Committee ( 2013-2015)
- Marshall University Graduate Medical Education Committee ( 2013-2015)

#### **Publications: Peer reviewed:**

---

Msherghi A, Wong F, Xu G, Mawlawi O, Elhadi M, **Alsharedi M**, Salim HA, Alizada S, Ray WJ, Puduvali VK, Wintermark M. <sup>18</sup>F-FDG PET Reveals Voxel-Based Decreases in Brain Glucose Uptake After Chemotherapy in Leukemia Patients: A Retrospective Matched-Control Study J Nucl Med. 2025 Oct 16;jnumed.125.270661. doi: 10.2967/jnumed.125.270661. PMID: 41101978

Jang Khan NA, Farooqi A, **Alsharedi M**. A Rare Case of Extensive Cerebral Venous Sinus Thrombosis Complicated by Heparin-Induced Thrombocytopenia. Case Rep Hematol. 2022 Jun 6;2022:7845786. doi: 10.1155/2022/7845786. eCollection 2022.PMID: 35707792

Sidda A, Manu G, Abdallah M, Griswold D, **Alsharedi M**, Pacioles T. Paraneoplastic Evans Syndrome in a Patient With Prostate Cancer With Small Cell Transformation Cureus. 2022 Apr 26;14(4):e24505. PMID: 35651454

Jang Khan NA, Farooqi A, **Alsharedi M**. A Rare Case of Extensive Cerebral Venous Sinus Thrombosis Complicated by Heparin-Induced Thrombocytopenia. Case Rep Hematol. 2022 Jun 6;2022:7845786 PMID: 35707792

Sidda A, Manu G, **Alsharedi M**, Dotson J, Nahar N. 2022 Jan-Dec.PMID: 35593442 DNA Methyl Transferase 3A (DNMT3A) Mutation Presenting as Isolated Pure Red Cell Aplasia. J Investig Med High Impact Case Rep.

Biglow L, Ashraf S, **Alsharedi M**. Checkpoint inhibitors: literature review of new treatments for hepatocellular carcinoma. *Stem Cell Investig*. 2021 Nov 10;8:22. PMID: 34917675

Ashraf S, **Alsharedi M**. Response of advanced cutaneous squamous cell carcinoma to immunotherapy: case report. *Stem Cell Investig*. 2021 Sep PMID: 34631872

Bukamur H, Alkrekshi A, Katz H, **Alsharedi M**, et al. Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: A Comprehensive Review, Part II *South Med J*. 2021 Sep;114(9):614-619. PMID: 34480197

Ashraf S, **Alsharedi M**. COVID-19 induced immune thrombocytopenic purpura: case report *Stem Cell Investig*. 2021 Jul 9;8:14. doi: 10.21037/sci-2020-060. eCollection 2021. PMID: 34386543

Nwanwene K, Khan NAJ, **Alsharedi M**. Testicular Plasmablastic Lymphoma in an HIV-Negative Patient: A Rare Case Presentation *J Investig Med High Impact Case Rep*. 2021 Jan-Dec;9:23247096211017423. doi: 10.1177/23247096211017423. PMID: 34032157

Jafri H, Khan I, Khan NAJ, Graffeo V, Hawkins J, **Alsharedi M**. Cutaneous Disease as a Rare Presentation of Follicular Lymphoma Progression *J Investig Med High Impact Case Rep*. 2021 Jan-Dec;9:2324709621997260. doi:10.1177/2324709621997260. PMID: 33629605

Alhousani M, Malik SU, Abu-Hashyeh A, Poznanski NJ, Al-Hasan S, Roth DF, **Alsharedi M**, Mustafa B. Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: A systematic review and meta-analysis *Thromb Res*. 2021 Feb;198:103-114. doi: 10.1016/j.thromres.2020.11.036. Epub 2020 Dec 2. PMID: 33310644

Bukamur H, Katz H, **Alsharedi M**, Alkrekshi A, Shweihat YR, Munn NJ. Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab. *South Med J*. 2020 Nov;113(11):600-605. doi: 10.14423/SMJ.0000000000001166. PMID: 33140115

Khan NAJ, **Alsharedi M**. Bullous Skin Rash: A Rare Case of Palbociclib-Induced Dermatological Toxicity *Cureus*. 2020 Sep 3;12(9):e10229. doi: 10.7759/cureus.10229. PMID: 32913695

Khan NAJ, Pacioles T, **Alsharedi M**. Atypical Takotsubo Cardiomyopathy Secondary to Combination of Chemo-Immunotherapy in a Patient With Non-Small Cell Lung Cancer *Cureus*. 2020 Jul 27;12(7):e9429. doi: 10.7759/cureus.9429. PMID: 32742890

Katz H, **Alsharedi M**, et al. Immune Checkpoint Inhibitors in Locally Advanced, Unresectable and Metastatic Upper Gastrointestinal Malignancies

Haydock M, Elhamdani S, **Alsharedi M**. Long-term anticoagulation in primary osteonecrosis with elevated plasminogen activator inhibitor. Sage Open Med Case Rep. 2019 Feb. PMID:30783528

Dotson J, **Alsharedi M**, et al. Neutropenic enterocolitis in patients with FLT3 mutated acute myeloid leukemia undergoing induction chemotherapy with midostaurin. Int J Hematol. 2018 Dec 3. doi: 10.1007/s12185-018-2558-4. PMID: 30506467

Katz H, **Alsharedi M**, et al. Solitary Lytic Bone Metastasis: A Rare Presentation of Small Lymphocytic Leukemia.

**Alsharedi M**, et al. Osimertinib for the treatment of patients with EGFR mutation-positive non-small cell lung cancer. Drugs Today (Barc). 2018 Jun;54(6):369-379. doi: 10.1358/dot.2018.54.6.2817668.PMID: 29998228

**Alsharedi M**, et al. Check point inhibitors a new era in renal cell carcinoma treatment. Med Oncol. 2018 May 4;35(6):85. doi: 10.1007/s12032-018-1147-y. Review. PMID: 29728867

**Alsharedi M**, et al. Durvalumab for the Treatment of Urothelial Carcinoma. Drugs Today (Barc). 2017 Dec;53(12):647-652. doi:10.1358/ dot. 2017.53.12.2733054. PMID:29517083

Katz H, **Alsharedi M**. Immunotherapy in Triple Negative Breast Cancer cancer. Med Oncol. 2017 Dec 18;35(1):13. doi: 10.1007/s12032-017-1071-6. Review. PMID: 29255938

Katz H, Wassie E, **Alsharedi M**. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer. Med Oncol. 2017 Sep 1;34(10):170. doi: 10.1007/s12032-017-1029- 8. Review. PMID:28864844

**Alsharedi M**, Shenouda M et al.Prognostic value of post treatment PET scan in small cell lung cancer. DOI: 10.1200/JCO.2017.35.15\_suppl.e20013 Journal of Clinical Oncology 35, no. 15\_suppl

Raufi A, **Alsharedi M**, Khelfa Y, Tirona M. Bilateral Triple-Negative Invasive Breast Cancer with a BRCA2 Mutation, and Glioblastoma: A Case Report and Literature Review. J Breast Cancer. 2017 Mar;20(1):108-111. doi: 10.4048/jbc.2017.20.1.108. Epub 2017 Mar 24. PMID:28382102

**Alsharedi M**, Elmsherghi N, Haydock MM, Bukamur H. Chemotherapy-related acute respiratory distress syndrome in germ cell tumors: a literature review. Med Oncol. 2017 Apr;34(4):56. doi: 10.1007/s12032-017-0913-6. Epub 2017 Mar 4. Review. PMID:28260213

Raufi A, **Alsharedi M**, Khelfa Y, Griswold DC, Lebowicz Y. Leukemia cutis in a patient with chronic lymphocytic leukemia presenting as bilateral helical nodules. SAGE Open

Med Case Rep. 2016 Dec 1;4:2050313X16683624. doi: 10.1177/2050313X16683624. eCollection 2016. PMID:28228955

**Alsharedi M**, Zgheib NB, Khelfa Y, Raufi A, Elmsherghi N, Lebowicz Y. Primary Retroperitoneal Melanoma Presented in a Rare Extracutaneous Site for Malignant Melanoma. *Rare Tumors*. 2016 Oct 5;8(3):6308. PMID:27746882

Talag MM, **Alsharedi M**, Bou Zgheib N, Lebowicz Y. Immunotherapy in a rare case of primary pelvic retroperitoneal melanoma. *BMJ Case Rep*. 2016 Sep 13;2016. pii:bcr2016216450. doi: 10.1136/bcr-2016-216450. PMID: 27624447

**Alsharedi M**, Gress T, Dotson J, Elmsherghi N, Tirona M. Comparison of Toxicity Profile and Tolerability between Two Standard of Care Paclitaxel Based Adjuvant Chemotherapy Regimens in Breast Cancer. *Med Oncol*. 2016 Mar;33(3):27. doi: 10.1007/s12032-016-0740-1. PMID: 26883934.

Khelfa Y, **Alsharedi M**, Mehmi I, Raufi A, Arrington A, Lebowicz Y, Pacioles T. Metastatic Sarcomatoid Carcinoma of the Small Intestine: a Case Report of Rare Tumor with Literature Review. *J Gastrointest Cancer*. 2015 Nov 6. PMID:26545611

Sehgal R, **Alsharedi M**, Larck C, Edwards P, Gress T. Pancreatic Cancer Survival in elderly Patients Treated with Chemotherapy. *Pancreas*. 2014 Mar; 43(2):306-10. PMID:24518512

**Alsharedi M**, Dotson J, Gress T, Tirona M. Standard of Care: 4 Doses of Dose-dense Paclitaxel in the Adjuvant Treatment of Breast Cancer Has Equal Toxicity Profile to Weekly Paclitaxel. *JNCCN*. November 2015 issue (AB2015-21).

Mozayen M, **Alsharedi M**, Mehmi I, Tirona M. Delaying Chemotherapy in the Treatment of Stage IV Non-Small Cell Lung Cancer Does Not Adversely Affect Survival Outcome. Status: Published: *West Virginia Medical Journal*. January/February 2016;112(1):34-37.

---

**Clinical Research:** Primary investigator and Co-investigator on many IRB approved clinical trials in my current and previous academic institutions ( University of Kentucky and Marshall University )